Costs of Cancer Care Across the Disease Continuum
dc.contributor.author | Kaye, Deborah R. | |
dc.contributor.author | Min, Hye Sung | |
dc.contributor.author | Herrel, Lindsey A. | |
dc.contributor.author | Dupree, James M. | |
dc.contributor.author | Ellimoottil, Chad | |
dc.contributor.author | Miller, David C. | |
dc.date.accessioned | 2018-08-13T18:48:15Z | |
dc.date.available | 2019-09-04T20:15:38Z | en |
dc.date.issued | 2018-07 | |
dc.identifier.citation | Kaye, Deborah R.; Min, Hye Sung; Herrel, Lindsey A.; Dupree, James M.; Ellimoottil, Chad; Miller, David C. (2018). "Costs of Cancer Care Across the Disease Continuum." The Oncologist 23(7): 798-805. | |
dc.identifier.issn | 1083-7159 | |
dc.identifier.issn | 1549-490X | |
dc.identifier.uri | https://hdl.handle.net/2027.42/145208 | |
dc.description.abstract | PurposeThe aim of this study was to estimate Medicare payments for cancer care during the initial, continuing, and end‐of‐life phases of care for 10 malignancies and to examine variation in expenditures according to patient characteristics and cancer severity.Materials and MethodsWe used linked Surveillance, Epidemiology and End Results‐Medicare data to identify patients aged 66–99 years who were diagnosed with one of the following 10 cancers: prostate, bladder, esophageal, pancreatic, lung, liver, kidney, colorectal, breast, or ovarian, from 2007 through 2012. We attributed payments for each patient to a phase of care (i.e., initial, continuing, or end of life), based on time from diagnosis until death or end of study interval. We summed payments for all claims attributable to the primary cancer diagnosis and analyzed the overall and phase‐based costs and then by differing demographics, cancer stage, geographic region, and year of diagnosis.ResultsWe identified 428,300 patients diagnosed with one of the 10 malignancies. Annual payments were generally highest during the initial phase. Mean expenditures across cancers were $14,381 during the initial phase, $2,471 for continuing, and $13,458 at end of life. Payments decreased with increasing age. Black patients had higher payments for four of five cancers with statistically significant differences. Stage III cancers posed the greatest annual cost burden for four cancer types. Overall payments were stable across geographic region and year.ConclusionConsiderable differences exist in expenditures across phases of cancer care. By understanding the drivers of such payment variations across patient and tumor characteristics, we can inform efforts to decrease payments and increase quality, thereby reducing the burden of cancer care.Implications for PracticeConsiderable differences exist in expenditures across phases of cancer care. There are further differences by varying patient characteristics. Understanding the drivers of such payment variations across patient and tumor characteristics can inform efforts to decrease costs and increase quality, thereby reducing the burden of cancer care.Using SEER‐Medicare data, this article demonstrates that considerable differences exist in expenditures across phases of care and varying patient characteristics. These findings can help to provide a better understanding of the drivers of payment variation across patient and tumor characteristics to inform efforts to decrease costs and increase quality of cancer care. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | Disease continuum | |
dc.subject.other | Cancer | |
dc.subject.other | Costs | |
dc.title | Costs of Cancer Care Across the Disease Continuum | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Hematology and Oncology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/145208/1/onco12395-sup-0001-suppinfo01.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/145208/2/onco12395.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/145208/3/onco12395-sup-0002-suppinfo02.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/145208/4/onco12395_am.pdf | |
dc.identifier.doi | 10.1634/theoncologist.2017-0481 | |
dc.identifier.source | The Oncologist | |
dc.identifier.citedreference | Abdollah F, Sammon JD, Majumder K et al. Racial disparities in end‐of‐life care among patients with prostate cancer: A population‐based study. J Natl Compr Canc Netw 2015; 13: 1131 – 1138. | |
dc.identifier.citedreference | Deloitte. The evolution of oncology payment models: What can we learn from early experiments? Available at https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-evolution-of-oncology-payment-models.pdf. Accessed June 6, 2017. | |
dc.identifier.citedreference | Farina KL. The economics of cancer care in the United States. Am J Manage Care 2012; 18: SP38 – SP39. | |
dc.identifier.citedreference | Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011; 103: 117 – 128. | |
dc.identifier.citedreference | Yabroff KR, Lamont EB, Mariotto AB et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100: 630 – 641. | |
dc.identifier.citedreference | Skolarus TA, Zhang Y, Miller DC et al. The economic burden of prostate cancer survivorship care. J Urol 2010; 184: 532 – 538. | |
dc.identifier.citedreference | Gottlieb DJ, Zhou W, Song Y et al. Prices don’t drive regional medicare spending variations. Health Aff (Millwood) 2010; 29: 537 – 543. | |
dc.identifier.citedreference | Xu X, Herrin J, Soulos PR et al. The role of patient factors, cancer characteristics, and treatment patterns in the cost of care for medicare beneficiaries with breast cancer. Health Serv Res 2016; 51: 167 – 186. | |
dc.identifier.citedreference | Sagar B, Lin YS, Castel LD. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6‐month episode: An economic analysis from the payer perspective. J Med Econ 2017; 20: 1018 – 1023. | |
dc.identifier.citedreference | Sheppard VB, Isaacs C, Luta G et al. Narrowing racial gaps in breast cancer chemotherapy initiation: The role of the patient‐provider relationship. Breast Cancer Res Treat 2013; 139: 207 – 216. | |
dc.identifier.citedreference | Green JB, Shapiro MF, Ettner SL et al. Physician variation in lung cancer treatment at the end of life. Am J Manag Care 2017; 23: 216 – 223. | |
dc.identifier.citedreference | Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091 – 1097. | |
dc.identifier.citedreference | Jazieh AR, Kyasa MJ, Sethuraman G et al. Disparities in surgical resection of early‐stage non–small cell lung cancer. J Thorac Cardiovasc Surg 2002; 123: 1173 – 1176. | |
dc.identifier.citedreference | Shugarman LR, Mack K, Sorbero ME et al. Race and sex differences in the receipt of timely and appropriate lung cancer treatment. Med Care 2009; 47: 774 – 781. | |
dc.identifier.citedreference | Rink M, Chun FK, Chromecki TF et al. Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies [in German]. Urologe A 2012; 51: 820 – 828. | |
dc.identifier.citedreference | May P, Garrido MM, Aldridge MD et al. Prospective cohort study of hospitalized adults with advanced cancer: Associations between complications, comorbidity, and utilization. J Hosp Med 2017; 12: 407 – 413. | |
dc.identifier.citedreference | Daniel CL, Gilreath K, Keyes D. Colorectal cancer disparities beyond biology: Screening, treatment, access. Front Biosci (Landmark Ed) 2017; 22: 465 – 478. | |
dc.identifier.citedreference | Taioli E, Flores R. Appropriateness of surgical approach in black patients with lung cancer—15 years later, little has changed. J Thorac Oncol 2017; 12: 573 – 577. | |
dc.identifier.citedreference | Brooks GA, Li L, Uno H et al. Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood) 2014; 33: 1793 – 1800. | |
dc.identifier.citedreference | Tangka FK, Trogdon JG, Richardson LC et al. Cancer treatment cost in the United States: Has the burden shifted over time? Cancer 2010; 116: 3477 – 3484. | |
dc.identifier.citedreference | Berger NA, Savvides P, Koroukian SM et al. Cancer in the elderly. Trans Am Clin Climatol Assoc 2006; 117: 147 – 156. | |
dc.identifier.citedreference | Kline R, Adelson K, Kirshner JJ et al. The Oncology Care Model: Perspectives from the Centers for Medicare & Medicaid Services and participating oncology practices in academia and the community. Am Soc Clin Oncol Educ Book 2017; 37: 460 – 466. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.